The Catalyst

Most Recent Posts

06.12.14 | By Robert Zirkelbach

All patients should have access to the medicines they need to manage their diseases, enabling them to live fuller, healthier, more productive lives. Unfortunately, recently-released data paints a very troubling picture of patients’ access to medicines in the new health insurance exchanges.  Too often patients are being forced to pay exorbitant out-of-pocket costs for live-saving medicines that not only improve patients’ health and quality of life, but help prevent unnecessary hospitalizations, ER visits, and costly medical procedures.

06.11.14 | By John Rice

As you read this, 30 outstanding middle school students from across the nation are busy studying amino acids, chromatography, and other scientific concepts in preparation for the National You Be The Chemist Challenge®—the final stage of the Chemical Educational Foundation’s® (CEF’s) exciting academic contest for grade 5 – 8 students.

06.11.14 | By Allyson Funk

This morning at the National Press Club, PhRMA CEO John J. Castellani joined patient groups to release new research from Avalere Health.

06.11.14 | By John Castellani

For millions of cancer patients and many others suffering from a chronic disease, access to new innovative treatments is critical. As an industry, we strongly believe that all patients should have access to the medicines they need to live long and healthy lives. Equally important, as discussions around health care costs continue, we must ensure that patients remain at the center of everything we do.

Cancer graphic
06.10.14 | By Jennifer Wall

If we want to have an honest discussion around cost, we must do so in a way that includes the entire spectrum of cancer care and not focused solely on the cost of cancer medicines.

06.09.14 | By Josh Schafer, MSc. MBA

With the recent conclusion of ASCO, we sat down with Josh Schafer, Astellas’ Vice President of Oncology Marketing Strategy, to get his perspective on the current state of affairs surrounding cancer research.

Path to 21st Century Cures
06.09.14 | By Dr. Bill Chin

PhRMA strongly supports the goals of the House Energy and Commerce Committee’s 21st Century Cures initiative that seeks to accelerate the discovery, development and delivery of new treatments and potential cures to patients.

06.06.14 | By Kaelan Hollon

Ensuring patients have access to innovative new medicines require collaboration within the biopharmaceutical industry and across the health care ecosystem. With the rapid pace of research and development, pooling resources and brainpower helps identify and utilize the most pertinent information. As a result, cooperation is occurring not only within the private sector, but also with non-profit organizations, academia and the government to more quickly bring treatments to patients in need.

06.06.14 | By Jay Taylor

The current intellectual property (IP) environment in Canada has caused increased friction with its closest allies, particularly in the area of IP rights protections for biopharmaceutical products. By revoking 19 patents since 2005 through questionable decisions, Canadian courts have set a disturbing precedent that risks future investments in cutting-edge R&D projects in innovative industries, and the high-paying jobs that accompany them.

06.05.14 | By Robert Zirkelbach

Our members are diligently working to bring new medicines to patients. To date, these treatments have helped make some of the most devastating diseases, including HIV, manageable conditions. To do the same for cancer, collaboration across the health care ecosystem is necessary.

06.05.14 | By Diane Stephenson, Ph.D.

Parkinson’s disease (PD) affects up to 1.5 million Americans and without any change, that number is expected to more than double by 2040.

06.04.14 | By Dr. Bill Chin

On June 1, patients around the world participated in a very special celebration, National Cancer Survivors Day. This is a day everyone in remission hopes for, and one those currently in treatment are working so hard to achieve.

In the United States alone, it is estimated there are 14 million people who have faced the challenges of a cancer diagnosis and are winning

06.04.14 | By Salvatore Alesci

The process of translating biomedical discoveries into novel therapies continues to increase in complexity as science and technology rapidly evolve. To ensure timely patient access to safe and effective innovative medical products, it is critical that the science of drug review and evaluation keeps up with rapid advances in drug discovery and development, so that experts across the ecosystem are able to understand, adopt and apply new scientific tools, standards, and approaches in evidence-based decision making processes.

06.03.14 | By Allyson Funk

Ensuring that patients have access to the medicines they need is at the heart of what biopharmaceutical research companies do every day. The Affordable Care Act put in place a new way for Americans to access health insurance coverage and even provides assistance in the form of tax credits and cost-sharing reductions for those who need it most.

05.31.14

Yesterday, ASCO held a panel entitled, “Can We Find Common Ground? Stakeholder Perspectives on Value in Cancer.” At the tail end, a woman stepped to the mike to make an observation to the panelists. Describing herself as a patient and an advocate, she declared that she heard little in the presentations about patient-reported outcomes, particularly in reference to ASCO's value initiative that is in the works.

Pages